global markets for vaccine technologies

ReportLinker Find Industry reports, Company profilesand Market Statistics

>> Get this Report Now by email!

Global Markets for Vaccine Technologies

Published on July 2013

Report Summary

A market evaluation for vaccine types/categories for humans and animals, including their respective regional sales, applications,

regulatory aspects, market forecasts (through 2017), prospects, innovation and challenges, patent analyses, clinical trials, market

leaders and market shares of vaccine sales.

Use this report to:

- Evaluate actual or potential markets for vaccine technologies in terms of specific application sectors and subsectors.

- Assess the current state of human and animal vaccine technologies.

- Learn about acquisitions, mergers, and alliances by companies and global organizations.

- Analyze significant patents and their allotments in each vaccine technology category.

- Know Comprehensive company profiles of major players.

Highlights

- Global revenue for vaccine technologies was nearly $31.8 billion in 2011. This market is expected to increase from $33.6 billion in

2012 to $43.4 billion in 2017 at a compound annual growth rate (CAGR) of 5.3%.

- Human vaccines led the market in 2011 with sales of $26.4 billion. Sales of human vaccines are expected to increase from $27.6

billion in 2012 to $33.8 billion in 2017, a CAGR of 4.1%.

- Sales of animal vaccines amounted to nearly $5.4 billion in 2011. Growth within the animal vaccine segment is expected to be the

highest over the forecast period and is projected to increase from $6.0 billion in 2012 to $9.6 billion in 2017, at a CAGR of 10.1%.

STUDY OBJECTIVES

This BCC study assesses and analyzes advancements in the human and animal vaccine industry. The report discusses the current

dynamics of the vaccine market and predicts the future market growth based on factors such as current products, trends in the

strategic moves of multinational companies, market share, product pipelines, consumer behavior and the immunization strategies of

various governmental and non-governmental organizations. This study also examines the key aspect of health safety for both human

and animal vaccination programs. The report presents the present market and its potential for growth, including revenue estimations,

product types/categories, market leaders, market shares and factors and drivers influencing the market for human and animal

vaccines. In addition, the report summarizes the scientific platforms, innovations, top-selling products and prospective candidates for

the present and future market. Vaccine market trends, coverage plans by key vaccine regulatory bodies, patents and health safety

concerns are also presented in the report. The opportunities and challenges presented to vaccine manufacturers and government

bodies, especially in the developing countries, are discussed within this report. The report presents the sales data of vaccine

manufacturing companies and other relevant sources where available. The vaccine market is analyzed by types or categories for

human and animal vaccines for the period of 2010 to 2012. In addition, revenue projections are given for 2017. The report also

presents data on regional sales of vaccines in North America (the U.S. and Canada), Europe and the emerging markets.

REASONS FOR DOING THIS STUDY

The progress in the vaccine industry from the perspective of usage, coverage, awareness and innovation over the past decade has

Global Markets for Vaccine Technologies (From Issuu) /21

http://www.reportlinker.com?utm_campaign=plp&utm_source=issuu&utm_medium=referral



http://www.reportlinker.com/p01595226/Global-Markets-for-Vaccine-Technologies.html#utm_campaign=plp&utm_source=issuu&utm_medium=referral




been noteworthy. The study covers the latest industry developments for human and animal vaccines, including updates on financial,

scientific, research and new product developments. Human vaccines offer a solution to improving health worldwide. The report offers

companies an analysis that they can use in strategizing their immunization plans going forward. The latest market trends, including

mergers/joint ventures, market penetration of large companies in the ever-growing developing markets, research, changing consumer

preferences, health and safety awareness and immunization coverage campaigns are driving the vaccine market. These trends are

opening up diverse opportunities for manufacturers and scientists to develop innovative and affordable products. This study

summarizes these factors for both the human and animal vaccine industries.

CONTRIBUTIONS OF THE STUDY AND FOR WHOM

This study emphasizes the necessity of vaccines in ensuring the health of both humans and animals. For human vaccines, the focus

is on the developing countries where access to vaccines is badly needed. For animals, vaccination is a health safety requirement to

ensure the health of animals and to avoid the transference of diseases from animals to humans, for both food producing animals and

companion animals. The study offers an overview of the vaccine industry for market participants such as manufacturers, researchers

and non-governmental organizations.

SCOPE OF THE STUDY

The report studies the various factors impacting the global market for human and animal vaccines. BCC conducted a market

evaluation for vaccine types/categories for humans and animals, including their respective regional sales, applications, regulatory

aspects, market forecasts, prospects, innovation and challenges, patent analyses, clinical trials, market leaders and market shares of

vaccine sales. The data gathered is for the global markets and statistically validated for the current and forecasted values. Similar

techniques were applied for regional data measurements and sales in the respective regions studied. Product details and scientific

techniques/platforms are provided based on their commercial and industrial viability. The emerging markets for orphan drugs include

India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand.

METHODOLOGY

BCC employed both primary as well as secondary research methodologies to gather relevant information on the vaccine industry. In

order to do that, BCC interviewed industry veterans, including scientists, manufacturers and others as well as conducted relevant

searches, including pharmaceutical and vaccine related newsletters, blogs, papers, journals, technical blogs, digests, news feeds,

technical articles, company white papers, research papers and other sources. Market projections reflect estimated unit prices, vaccine

usage and potential immunization coverage, the present market economy, future application of vaccines and market direction and

trends.

INFORMATION SOURCES

BCC researched companies associated with the vaccine industry to acquire data for this study. These companies were mostly

manufacturers and end users of vaccines for both humans and animals. BCC contacted industry representatives of vaccine

companies, scientists and research teams to gain better insight into the prospects and development of the industry. In addition, BCC

consulted scientific papers, research papers and articles, science journal, medical and pharmaceutical papers and journals, company

white papers, financial reports, newsletters, company literature, medical and pharmaceutical blogs, product literature, technical

articles, periodicals, bulletins, abstracts, regulations, patent files, etc. Pharmaceutical and medical related database searches were

also key contributors for the research work









Table of Content

CHAPTER 1 INTRODUCTION 2

STUDY OBJECTIVES 2

REASONS FOR DOING THIS STUDY 2

CONTRIBUTIONS OF THE STUDY AND FOR WHOM 3

SCOPE OF THE STUDY 3

METHODOLOGY 3

INFORMATION SOURCES 3

ABOUT THE AUTHOR 4

RELATED BCC RESEARCH REPORTS 4

BCC ONLINE SERVICES 4

DISCLAIMER 5

CHAPTER 2 EXECUTIVE SUMMARY 7

SUMMARY TABLE GLOBAL SALES OF HUMAN AND ANIMAL VACCINES, THROUGH

2017 ($ MILLIONS) 9

SUMMARY FIGURE GLOBAL SALES OF HUMAN AND ANIMAL VACCINES, 2010-2017

($ MILLIONS) 9

CHAPTER 3 OVERVIEW 11

DEFINITION OF A VACCINE 11

DEFINITION OF IMMUNITY 11

ACTIVE 11

PASSIVE 11

HOW VACCINES WORK 12

IMPORTANCE OF VACCINES 12

HISTORY OF VACCINES 12

TABLE 1 HISTORY OF VACCINES 12

TYPES OF VACCINES 14

ATTENUATED (LIVE) VACCINES 14

Types of Attenuated (Live) Vaccines 15

TABLE 2 TYPES OF ATTENUATED (LIVE) VACCINES 15

Advantages and Disadvantages of Attenuated (Live) Vaccines 16

TABLE 3 ADVANTAGES AND DISADVANTAGES OF ATTENUATED (LIVE) VACCINES 16

INACTIVATED (KILLED) VACCINES 17

Types of Inactivated (Killed) Vaccines 17

TABLE 4 TYPES OF INACTIVATED (KILLED) VACCINES 17

Advantages and Disadvantages of Inactivated (Killed) Vaccines 18

TABLE 5 ADVANTAGES AND DISADVANTAGES OF INACTIVATED (KILLED) VACCINES 18

TOXOID VACCINES 18

Types of Toxoid Vaccines 19

TABLE 6 TYPES OF TOXOID VACCINES 19

Advantages and Disadvantages of Toxoid Vaccines 19

TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES 19

SUBUNIT VACCINES 20

Types of Subunit Vaccines 20

TABLE 8 TYPES OF SUBUNIT VACCINES 20









Advantages and Disadvantages of Subunit Vaccines 21

TABLE 9 ADVANTAGES AND DISADVANTAGES OF SUBUNIT VACCINES 21

CONJUGATE VACCINES 21

Types of Conjugate Vaccines 22

TABLE 10 TYPES OF CONJUGATE VACCINES 22

Advantages and Disadvantages of Conjugate Vaccines 22

TABLE 11 ADVANTAGES AND DISADVANTAGES OF CONJUGATE VACCINES 22

RECOMBINANT VECTOR VACCINES 22

Types of Recombinant Vector Vaccines 23

TABLE 12 TYPES OF RECOMBINANT VECTOR VACCINES 23

Advantages and Disadvantages of Recombinant Vector Vaccines 24

TABLE 13 ADVANTAGES AND DISADVANTAGES OF RECOMBINANT VECTOR

VACCINES 24

DNA VACCINES 24

Types of DNA Vaccines 25

TABLE 14 TYPES OF DNA VACCINES 25

Advantages and Disadvantages of DNA vaccines 25

TABLE 15 ADVANTAGES AND DISADVANTAGES OF DNA VACCINES 25

INFECTIOUS DISEASES PREVENTABLE BY VACCINES 26

HUMAN DISEASES 26

Viral Diseases 26

TABLE 16 VACCINE-PREVENTABLE HUMAN VIRAL DISEASES 27

Bacterial Diseases 28

TABLE 17 VACCINE-PREVENTABLE HUMAN BACTERIAL DISEASES 29

ANIMAL DISEASES 31

Food Producing Animals 32

TABLE 18 VACCINE-PREVENTABLE ANIMAL DISEASES FOUND IN FOOD PRODUCING

ANIMALS 32

Companion Animals 34

TABLE 19 VACCINE-PREVENTABLE ANIMAL DISEASES FOUND IN COMPANION

ANIMALS 35

Other Animals 35

TABLE 20 VACCINE-PREVENTABLE ANIMAL DISEASES FOUND IN OTHER ANIMALS 36

TABLE 21 ANIMAL VACCINES FOR FOOD-PRODUCING, COMPANION AND OTHER

ANIMALS 37

CHAPTER 4 REGULATORY ASPECTS 44

REGULATORY ASPECTS 44

TABLE 22 NATIONAL REGULATORY AUTHORITIES OF VACCINES ACROSS REGIONS 44

TABLE 23 REVISIONS TO EXISTING VACCINES, 2010 THROUGH 2012 46

TABLE 24 NEWLY APPROVED VACCINES, 2010 THROUGH 2012 51

TABLE 25 GLOBAL VACCINE RECALLS, 2010 THROUGH 2012 52

REGULATORY DEVELOPMENTS IN VACCINE-PREVENTABLE DISEASE PRODUCTS 53

CHAPTER 5 PREVALENCE 56

INCIDENCE AND IMMUNIZATION OF HUMAN DISEASES 56

REGIONAL DATA 56

TABLE 26 REPORTED INCIDENCE DATA OF HUMAN DISEASES (NO.) 56

TABLE 27 IMMUNIZATION COVERAGE DATA OF HUMAN DISEASES (%) 57

GLOBAL DATA 58









TABLE 28 REPORTED CASES OF VACCINE-PREVENTABLE HUMAN DISEASES

WORLDWIDE, 2010 AND 2011 (NO.) 58

TABLE 29 IMMUNIZATION COVERAGE OF VACCINE-PREVENTABLE HUMAN

DISEASES WORLDWIDE, 2010 AND 2011 (%) 59

GLOBAL IMMUNIZATION UPTAKE DATA 59

TABLE 30 UPTAKE OF NEW AND UNDERUSED VACCINES, 2011 (NO.) 59

GLOBAL DEATHS DUE TO VACCINE-PREVENTABLE DISEASES 60

TABLE 31 DEATHS OF CHILDREN GLOBALLY DUE TO DISEASES PREVENTABLE WITH

VACCINES, 2011 (NO.) 60

TABLE 32 ESTIMATED FUTURE DEATHS AVERTED WITH VACCINES, 2011-2020

(MILLIONS) 61

CHAPTER 6 NEW DEVELOPMENTS 63

NEW DEVELOPMENTS 63

TABLE 33 HUMAN VACCINES IN THE RESEARCH PIPELINE AS OF 2012 64

TABLE 34 ALLIANCES, JOINT VENTURES AND AWARDS FOR THE DEVELOPMENT OF

HUMAN AND ANIMAL VACCINES, 2010-2012 71

NEW COLLABORATIVE TRIALS 72

CHAPTER 7 GLOBAL MARKETS FOR HUMAN AND ANIMAL VACCINES 75

VACCINE MARKET BY CATEGORY 76

MARKET OVERVIEW 76

Recent Developments in Animal Vaccines 77

MARKET REVENUE 77

TABLE 35 GLOBAL SALES OF VACCINES BY CATEGORY, THROUGH 2017 ($

MILLIONS) 78

FIGURE 1 GLOBAL SALES OF VACCINES BY CATEGORY, 2010-2017 ($ MILLIONS) 78

MARKET SHARE 78

TABLE 36 GLOBAL MARKET SHARES OF VACCINE SALES BY CATEGORY, 2011 (%) 79

FIGURE 2 GLOBAL MARKET SHARES OF VACCINE SALES BY CATEGORY, 2011 (%) 79

MARKET BY TYPE 79

MARKET FOR HUMAN VACCINES 79

Market Overview 80

Market Revenue 82

TABLE 37 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, THROUGH 2017 ($

MILLIONS) 82

FIGURE 3 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, 2010-2017 ($

MILLIONS) 82

Market Share 83

TABLE 38 GLOBAL MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE,

2011 (%) 83

FIGURE 4 GLOBAL MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2011

(%) 84

MARKET FOR ANIMAL HEALTH PRODUCTS 84

Market Overview 85

Market Revenue 86

TABLE 39 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, THROUGH 2017 ($

MILLIONS) 86

FIGURE 5 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, 2010-2017 ($

MILLIONS) 86









Market Share 87

TABLE 40 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE,

2011 (%) 87

FIGURE 6 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2011

(%) 87

MARKET BY REGION 88

MARKET OVERVIEW 88

Human Vaccines 89

Animal Vaccines 89

MARKET REVENUE 90

TABLE 41 GLOBAL SALES OF VACCINES BY REGION, THROUGH 2017 ($ MILLIONS) 90

FIGURE 7 GLOBAL SALES OF VACCINES BY REGION, 2010-2017 ($ MILLIONS) 90

MARKET SHARE 91

TABLE 42 GLOBAL MARKET SHARES OF VACCINE SALES BY REGION, 2011 (%) 91

FIGURE 8 GLOBAL MARKET SHARES OF VACCINE SALES BY REGION, 2011 (%) 91

MARKET BY APPLICATION 92

HUMAN VACCINES 92

MARKET OVERVIEW 93

MARKET REVENUE 94

TABLE 43 GLOBAL SALES OF HUMAN VACCINES BY APPLICATION, THROUGH 2017

($ MILLIONS) 94

FIGURE 9 GLOBAL SALES OF HUMAN VACCINES BY APPLICATION, 2010-2017 ($

MILLIONS) 95

MARKET SHARE BY APPLICATION 95

TABLE 44 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION,

2011 (%) 96

FIGURE 10 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION,

2011 (%) 96

MARKET SHARES OF TOP-SELLING VACCINES BY APPLICATION 96

TABLE 45 MARKET SHARES OF TOP-SELLING VACCINES BY APPLICATION, 2011 (%) 97

CHAPTER 8 MARKET ANALYSIS OF HUMAN VACCINES 99

MARKET BY TYPE 99

MARKET OVERVIEW 99

MARKET REVENUE 100


MILLIONS) 101

FIGURE 11 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, 2010-2017 ($

MILLIONS) 102

MARKET SHARE 102

TABLE 47 MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2011 (%) 102

FIGURE 12 MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2011 (%) 103

MARKET BY REGION 103

MARKET OVERVIEW 103

MARKET REVENUE 104

TABLE 48 GLOBAL SALES OF HUMAN VACCINES BY REGION, THROUGH 2017 ($

MILLIONS) 105

FIGURE 13 GLOBAL SALES OF HUMAN VACCINES BY REGION, 2010-2017 ($

MILLIONS) 105









MARKET SHARE 105

TABLE 49 MARKET SHARES OF HUMAN VACCINE SALES BY REGION, 2011 (%) 106

FIGURE 14 MARKET SHARES OF HUMAN VACCINE SALES BY REGION, 2011 (%) 106

Regional Markets for Attenuated (Live) Vaccines 106

Market Overview 107

Market Revenue 108

TABLE 50 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINES BY REGION,

THROUGH 2017 ($ MILLIONS) 108

FIGURE 15 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINES BY REGION,

2010-2017 ($ MILLIONS) 108

Regional Markets for Inactivated Vaccines 109

Market Overview 109

Market Revenue 110

TABLE 51 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES BY REGION,


FIGURE 16 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES BY REGION,

2010-2017 ($ MILLIONS) 111

Regional Markets for Conjugate Vaccines 111

Market Overview 112

Market Revenue 112

TABLE 52 GLOBAL MARKET FOR CONJUGATE VACCINES BY REGION, THROUGH

2017 ($ MILLIONS) 113

FIGURE 17 GLOBAL MARKET FOR CONJUGATE VACCINES BY REGION, 2010-2017 ($

MILLIONS) 113

Regional Markets for rDNA/DNA Vaccines 114

Market Overview 114

Market Revenue 115

TABLE 53 GLOBAL MARKET FOR RECOMBINANT/RDNA/DNA VACCINES BY REGION,


FIGURE 18 GLOBAL MARKET FOR RECOMBINANT/RDNA/DNA VACCINES BY REGION,

2010-2017 ($ MILLIONS) 116

Regional Markets for Subunit Vaccines 116

Market Overview 116

Market Revenue 117

TABLE 54 GLOBAL MARKET FOR SUBUNIT VACCINES BY REGION, THROUGH 2017

($ MILLIONS) 118

FIGURE 19 GLOBAL MARKET FOR SUBUNIT VACCINES BY REGION, 2010-2017 ($

MILLIONS) 118

Regional Markets for Toxoid Vaccines 118

Market Overview 119

Market Revenue 119

TABLE 55 GLOBAL MARKET FOR TOXOID VACCINES BY REGION, THROUGH 2017 ($

MILLIONS) 119

FIGURE 20 GLOBAL MARKET FOR TOXOID VACCINES BY REGION, 2010-2017 ($

MILLIONS) 120

Regional Markets for Other/Combination Vaccines 120

Market Overview 120

Market Revenue 121









TABLE 56 GLOBAL MARKET FOR OTHER/COMBINATION VACCINES BY REGION,


FIGURE 21 global market for other/combination vaccines by region, 2010-2017 ($

MILLIONS) 121

MARKET BY APPLICATION 122

PROPHYLACTIC VACCINES 122

THERAPEUTIC VACCINES 123

TABLE 57 HUMAN VACCINES BASED ON MICROORGANISM 123

MENINGOCOCCAL/PNEUMOCOCCAL DISEASES 124

Meningococcal 124

Pneumococcal Diseases 125

Noninvasive Pneumococcal Diseases 125

Invasive Pneumococcal Diseases 125

Market Revenue 126

TABLE 58 GLOBAL SALES OF HUMAN VACCINES FOR

MENINGOCOCCAL/PNEUMOCOCCAL DISEASES, THROUGH 2017 ($ MILLIONS) 126

FIGURE 22 GLOBAL SALES OF HUMAN VACCINES FOR

MENINGOCOCCAL/PNEUMOCOCCAL DISEASES MARKET, 2010-2017 ($ MILLIONS) 127

INFLUENZA (SEASONAL AND PANDEMIC) DISEASES 128

Market Revenue 129

TABLE 60 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET,


FIGURE 23 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET,

2010-2017 ($ MILLIONS) 130

Market Share 130

TABLE 61 MARKET SHARES OF TOP-SELLING INFLUENZA VACCINES, 2011 (%) 131

PEDIATRIC POLIO/PERTUSSIS/HIB 131

Market Revenue 133

TABLE 62 GLOBAL SALES OF HUMAN VACCINES PEDIATRIC POLIO/PERTUSSIS/HIB

DISEASES MARKET, THROUGH 2017 ($ MILLIONS) 133

FIGURE 24 GLOBAL SALES OF HUMAN VACCINES PEDIATRIC POLIO/PERTUSSIS/HIB

DISEASES MARKET, 2010-2017 ($ MILLIONS) 133

Market Share 134

TABLE 63 MARKET SHARES OF TOP-SELLING PEDIATRIC POLIO/PERTUSSIS/HIB

VACCINES, 2011 (%) 134

ADULT/ADOLESCENT BOOSTER VACCINES 135

Market Revenue 135

TABLE 64 GLOBAL SALES OF HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER


FIGURE 25 GLOBAL SALES OF HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER

DISEASES MARKET, 2010-2017 ($ MILLIONS) 136

Market Share 137

TABLE 65 MARKET SHARES OF TOP-SELLING ADULT/ADOLESCENT BOOSTER

VACCINES, 2011 (%) 137

TRAVEL-RELATED AND OTHER ENDEMIC DISEASES 137

Market Revenue 139

TABLE 66 GLOBAL SALES OF HUMAN VACCINES FOR TRAVEL-RELATED AND OTHER

ENDEMIC DISEASES, THROUGH 2017 ($ MILLIONS) 139









FIGURE 26 GLOBAL SALES OF HUMAN VACCINES FOR TRAVEL-RELATED AND

OTHER ENDEMIC DISEASES, 2010-2017 ($ MILLIONS) 140

Market Share 140

TABLE 67 MARKET SHARES OF TOP-SELLING VACCINES FOR TRAVEL-RELATED AND

OTHER ENDEMIC DISEASES, 2011 (%) 141

HPV DISEASE 141

Market Revenue 142

TABLE 68 GLOBAL SALES OF HUMAN VACCINES IN HPV, THROUGH 2017 ($

MILLIONS) 142

FIGURE 27 GLOBAL SALES OF HUMAN VACCINES IN HPV, 2010-2017 ($ MILLIONS) 142

Market Share 143

TABLE 69 MARKET SHARES OF TOP-SELLING HPV VACCINES, 2011 (%) 143

ROTAVIRUS DISEASE 143

Market Revenue 144

TABLE 70 GLOBAL SALES OF HUMAN VACCINES IN ROTAVIRUS MARKET, THROUGH

2017 ($ MILLIONS) 144

FIGURE 28 GLOBAL SALES OF HUMAN VACCINES IN ROTAVIRUS MARKET,

2010-2017 ($ MILLIONS) 144

Market Share 145

TABLE 71 MARKET SHARES OF TOP-SELLING ROTAVIRUS VACCINES, 2011 (%) 145

OTHER DISEASES 145

Recent Developments 146

Market Revenue 147

TABLE 72 GLOBAL SALES OF HUMAN VACCINES IN THE OTHER DISEASES SEGMENT,


FIGURE 29 GLOBAL SALES OF HUMAN VACCINES IN THE OTHER DISEASES

SEGMENT, 2010-2017 ($ MILLIONS) 147

Market Share 148

TABLE 73 MARKET SHARES OF TOP-SELLING VACCINES IN THE OTHER DISEASES

SEGMENT, 2011 (%) 149

MARKET SHARE OF APPLICATIONS 149


2011 (%) 150

FIGURE 30 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION,

2011 (%) 150

INDUSTRY STRUCTURE 150

MARKET LEADERS 151

TABLE 75 LEADING MANUFACTURERS/SUPPLIERS OF HUMAN VACCINES 151

MARKET SHARES 157

TABLE 76 MANUFACTURER/PROCESSORS' MARKET SHARES OF HUMAN VACCINE

SALES, 2011 (%) 157

FIGURE 31 MANUFACTURERS/PROCESSORS' MARKET SHARES OF HUMAN VACCINE

SALES, 2011 (%) 158

CHAPTER 9 MARKET ANALYSIS OF ANIMAL VACCINES 160

MARKET OVERVIEW 160

MARKET REVENUE 161

TABLE 77 GLOBAL SALES OF ANIMAL HEALTH PRODUCTS BY MARKET LEADER,

2010'2012 ($ MILLIONS) 162









FIGURE 32 GLOBAL SALES OF ANIMAL HEALTH PRODUCTS BY MARKET LEADER,

2010-2012 ($ MILLIONS) 162

ANIMAL VACCINES 163

MARKET BY TYPE 164


MILLIONS) 165

FIGURE 33 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, 2010-2017 ($

MILLIONS) 165

Vaccines Used in Food Producing Animals 166

Market Overview 166

Market Revenue 167

TABLE 79 GLOBAL MARKET FOR VACCINES FOR FOOD-PRODUCING ANIMALS BY

REGION, THROUGH 2017 ($ MILLIONS) 167

FIGURE 34 GLOBAL MARKET FOR VACCINES FOR FOOD-PRODUCING ANIMALS BY

REGION, 2010'2017 ($ MILLIONS) 167

Companion Animal Vaccines 168

Market Overview 168

Market Revenue 169

TABLE 80 GLOBAL MARKET FOR VACCINES FOR COMPANION ANIMALS BY REGION,


FIGURE 35 GLOBAL MARKET FOR VACCINES FOR COMPANION ANIMALS BY REGION,

2010-2017 ($ MILLIONS) 170

Other Animal Vaccines 170

Market Overview 170

Market Revenue 171

TABLE 81 GLOBAL MARKET FOR OTHER ANIMAL VACCINES BY REGION, THROUGH

2017 ($ MILLIONS) 171

FIGURE 36 GLOBAL MARKET FOR OTHER ANIMAL VACCINES BY REGION,

2010-2017 ($ MILLIONS) 171

Market Share 172

TABLE 82 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE,

2011 (%) 172

FIGURE 37 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE,

2011 (%) 172

MARKET BY REGION 173

Market Overview 173

Market Revenue 174

TABLE 83 GLOBAL SALES OF ANIMAL VACCINES BY REGION, THROUGH 2017 ($

MILLIONS) 175

FIGURE 38 GLOBAL SALES OF ANIMAL VACCINES BY REGION, 2010-2017 ($

MILLIONS) 175

Market Share 175

TABLE 84 MARKET SHARES OF ANIMAL VACCINE SALES BY REGION, 2011 (%) 176

FIGURE 39 MARKET SHARES OF ANIMAL VACCINE SALES BY REGION, 2011 (%) 176

INDUSTRY STRUCTURE 176

MARKET LEADERS 176

TABLE 85 LEADING MANUFACTURERS/SUPPLIERS OF ANIMAL VACCINES 176

MARKET SHARES 178









TABLE 86 MANUFACTURER/PROCESSORS' MARKET SHARES OF ANIMAL VACCINE

SALES, 2011 (%) 179

FIGURE 40 MANUFACTURER/PROCESSORS' MARKET SHARES OF ANIMAL VACCINE

SALES, 2011 (%) 180

CHAPTER 10 PATENT ANALYSIS 182

PATENTS BY YEAR 182

TABLE 87 U.S. PATENTS GRANTED FOR HUMAN AND ANIMAL VACCINES BY YEAR,

2010'2012 (NO.) 183

FIGURE 41 U.S. PATENTS GRANTED FOR HUMAN AND ANIMAL VACCINES BY YEAR,

2010-2012 (NO.) 183

PATENTS BY VACCINE TYPE 183

TABLE 88 U.S. PATENTS GRANTED FOR HUMAN AND ANIMAL VACCINES BY TYPE,

2010'2012 (NO.) 184

FIGURE 42 U.S. PATENTS GRANTED FOR HUMAN AND ANIMAL VACCINES BY TYPE,

2010-2012 (NO.) 184

PATENTS BY ASSIGNEE'S COUNTRY 185


TABLE 89 U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY

ASSIGNEE'S COUNTRY, 2010'2012 (NO.) 185

FIGURE 43 U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY

ASSIGNEE'S COUNTRY, 2010-2012 (NO.) 185

TABLE 90 SHARES OF U.S. PATENTS ON ATTENUATED (LIVE) VACCINES BY

ASSIGNEE'S COUNTRY, 2010-2012 (NUMBER/%) 186

FIGURE 44 SHARES OF U.S. PATENTS ON ATTENUATED (LIVE) VACCINES BY

ASSIGNEE'S COUNTRY, 2010-2012 (%) 187


TABLE 91 U.S. PATENTS GRANTED FOR INACTIVATED (KILLED) VACCINES BY


FIGURE 45 U.S. PATENTS GRANTED FOR INACTIVATED (KILLED) VACCINES BY


TABLE 92 SHARES OF U.S. PATENTS ON INACTIVATED (KILLED) VACCINES BY

ASSIGNEE'S COUNTRY, 2010'2012 (NUMBER/%) 189

FIGURE 46 SHARES OF U.S. PATENTS ON INACTIVATED (KILLED) VACCINES BY


TOXOID VACCINES 190

TABLE 93 U.S. PATENTS GRANTED FOR TOXOID VACCINES BY ASSIGNEE'S

COUNTRY, 2010'2012 (NO.) 190

FIGURE 47 U.S. PATENTS GRANTED FOR TOXOID VACCINES BY ASSIGNEE'S

COUNTRY, 2010-2012 (NO.) 190

TABLE 94 SHARES OF U.S. PATENTS ON TOXOID VACCINES BY ASSIGNEE'S

COUNTRY, 2010'2012 (%) 191

FIGURE 48 SHARES OF U.S. PATENTS ON TOXOID VACCINES BY ASSIGNEE'S

COUNTRY, 2010-2012 (%) 191

SUBUNIT VACCINES 192

TABLE 95 U.S. PATENTS GRANTED FOR SUBUNIT VACCINES BY ASSIGNEE'S

COUNTRY, 2010'2012 (NO.) 192

FIGURE 49 U.S. PATENTS GRANTED FOR SUBUNIT VACCINES BY ASSIGNEE'S

COUNTRY, 2010-2012 (NO.) 193









TABLE 96 SHARES OF U.S. PATENTS ON SUBUNIT VACCINES BY ASSIGNEE'S

COUNTRY, 2010'2012 (%) 193

FIGURE 50 SHARES OF U.S. PATENTS ON SUBUNIT VACCINES BY ASSIGNEE'S

COUNTRY, 2010-2012 (%) 193


TABLE 97 U.S. PATENTS GRANTED FOR CONJUGATE VACCINES BY ASSIGNEE'S

COUNTRY, 2010'2012 (NO.) 194

FIGURE 51 U.S. PATENTS GRANTED FOR CONJUGATE VACCINES BY ASSIGNEE'S

COUNTRY, 2010-2012 (NO.) 195

TABLE 98 SHARES OF U.S. PATENTS ON CONJUGATE VACCINES BY ASSIGNEE'S

COUNTRY, 2010'2012 (%) 195

FIGURE 52 SHARES OF U.S. PATENTS ON CONJUGATE VACCINES BY ASSIGNEE'S

COUNTRY, 2010-2012 (%) 196

RECOMBINANT/RDNA/DNA VACCINES 196

TABLE 99 U.S. PATENTS GRANTED FOR RECOMBINANT/RDNA/DNA VACCINES BY


FIGURE 53 U.S. PATENTS GRANTED FOR RECOMBINANT/RDNA/DNA VACCINES BY


TABLE 100 SHARES OF U.S. PATENTS ON RECOMBINANT/RDNA/DNA VACCINES BY

ASSIGNEE'S COUNTRY, 2010'2012 (%) 198

FIGURE 54 SHARES OF U.S. PATENTS ON RECOMBINANT/RDNA/DNA VACCINES BY


OTHER/COMBINATION VACCINES 199

TABLE 101 U.S. PATENTS GRANTED FOR OTHER/COMBINATION VACCINES BY


FIGURE 55 U.S. PATENTS GRANTED FOR OTHER/COMBINATION VACCINES BY


TABLE 102 SHARES OF U.S. PATENTS ON OTHER/COMBINATION VACCINES BY


FIGURE 56 SHARES OF U.S. PATENTS ON OTHER/COMBINATION VACCINES BY


PATENTS BY COMPANY 202



COMPANY, 2010'2012 (NO.) 202


COMPANY, 2010-2012 (NO.) 203


TABLE 104 U.S. PATENTS GRANTED ON INACTIVATED (KILLED) VACCINES BY

COMPANY, 2010'2012 (NO.) 204

FIGURE 58 U.S. PATENTS GRANTED ON INACTIVATED (KILLED) VACCINES BY

COMPANY, 2010-2012 (NO.) 204


TABLE 105 U.S. PATENTS GRANTED ON SUBUNIT VACCINES BY COMPANY,

2010'2012 (NO.) 205

FIGURE 59 U.S. PATENTS GRANTED ON SUBUNIT VACCINES BY COMPANY,

2010-2012 (NO.) 206










TABLE 106 U.S. PATENTS GRANTED ON CONJUGATE VACCINES BY COMPANY,

2010'2012 (NO.) 206FIGURE 60 U.S. PATENTS GRANTED ON CONJUGATE VACCINES BY COMPANY,

2010-2012 (NO.) 207


TABLE 107 U.S. PATENTS GRANTED ON RECOMBINANT/RDNA/DNA VACCINES BY

COMPANY, 2010'2012 (NO.) 208

FIGURE 61 U.S. PATENTS GRANTED ON RECOMBINANT/RDNA/DNA VACCINES BY

COMPANY, 2010-2012 (NO.) 208


TABLE 108 U.S. PATENTS GRANTED ON OTHER/COMBINATION VACCINES BY

COMPANY, 2010'2012 (NO.) 209

FIGURE 62 U.S. PATENTS GRANTED ON OTHER/COMBINATION VACCINES BY

COMPANY, 2010-2012 (NO.) 210

PATENTS BY ASSIGNEE 211



ASSIGNEE TYPE, 2010'2012 (NO.) 212






FIGURE 64 U.S. PATENTS GRANTED FOR INACTIVATED (KILLED) VACCINES BY

ASSIGNEE TYPE, 2010-2012 (NO.) 213

TOXOID VACCINES 213

TABLE 111 U.S. PATENTS GRANTED FOR TOXOID VACCINES BY ASSIGNEE TYPE,

2010'2012 (NO.) 214

FIGURE 65 U.S. PATENTS GRANTED FOR TOXOID VACCINES BY ASSIGNEE TYPE,

2010-2012 (NO.) 214


TABLE 112 U.S. PATENTS GRANTED FOR SUBUNIT VACCINES BY ASSIGNEE TYPE,

2010'2012 (NO.) 215

FIGURE 66 U.S. PATENTS GRANTED FOR SUBUNIT VACCINES BY ASSIGNEE TYPE,

2010-2012 (NO.) 215


TABLE 113 U.S. PATENTS GRANTED FOR CONJUGATE VACCINES BY ASSIGNEE TYPE,

2010'2012 (NO.) 216

FIGURE 67 U.S. PATENTS GRANTED FOR CONJUGATE VACCINES BY ASSIGNEE TYPE,

2010-2012 (NO.) 216




FIGURE 68 U.S. PATENTS GRANTED FOR RECOMBINANT/RDNA/DNA VACCINES BY





FIGURE 69 U.S. PATENTS GRANTED FOR OTHER/COMBINATION VACCINES BY










CHAPTER 11 CURRENT SITUATION 220

ORGANIZATIONS DEDICATED TO GLOBAL IMMUNIZATIONS FOR HUMANS 220

GLOBAL IMMUNIZATION VISION AND STRATEGY (GIVS) 220

GIVS Aims-2006 through 2012 221

GIVS Goals by 2015 or earlier 221

GIVS Strategies 221

GIVS Global Immunization Progress 221

GLOBAL VACCINE ACTION PLAN (GVAP) 222

Six Guiding Principles of GVAP 222

GVAP Goals-2011 through 2020 222

TABLE 116 GVAP GOAL LEVEL TARGETS 223

GVAP Strategic Objectives-2011 through 2010 223

THE GLOBAL ALLIANCE FOR VACCINES AND IMMUNISATION (GAVI) 224

GAVI Potential Forecast-2011 through 2015 224

GAVI Focus 225

GAVI Progress 225

FUNDING AND CHALLENGES 225

UPDATE ON VACCINE-PREVENTABLE DISEASES IN HUMANS 226

WHO PREQUALIFIED MANUFACTURERS OF HUMAN VACCINES 226

TABLE 117 WHO-PREQUALIFIED MANUFACTURERS/SUPPLIERS OF HUMAN

VACCINES, 2012 227

FUTURE VACCINE PRIORITIZATION 227

TABLE 118 VACCINE PRIORITIZATION, 2013-2014 228

CURRENT AND FUTURE (PROPOSED) VACCINE ACHIEVEMENTS AND

CHALLENGES 229

TABLE 119 VACCINE ACHIEVEMENTS AND CHALLENGES THROUGH 2012 230

WHO VACCINE RESEARCH AND PROGRESS 232

TABLE 120 WHO VACCINE RESEARCH AND PROGRESS 232

NEW VACCINE TECHNOLOGIES AND PLATFORMS 232

PROGRESS IN HUMAN VACCINES 233

Peptide Vaccines 233

New Molecular Technique to Control and Develop Malaria Vaccine 233

Hydrogen Peroxide-Based Vaccine Platform 233

PROGRESS IN ANIMAL VACCINES 234

FACTORS AFFECTING THE VACCINE MARKET 234

HIGH PRICES OF NEWER VACCINES 234

LACK OR RESEARCH OPPORTUNITIES 234

WEAK LOCAL HEALTH CENTERS 235

ISSUES WITH MIDDLE INCOME COUNTRIES 235

HURDLES FOR NEW ENTRANTS 235

CURRENT DRIVERS OF THE VACCINE MARKET 235

DRIVERS OF THE MARKET FOR HUMAN VACCINES 235

DRIVERS OF THE MARKET FOR ANIMAL VACCINES 236

ACQUISITIONS/COLLABORATIONS 236

CHAPTER 12 COMPANY PROFILES 239

ABBOTT LABORATORIES 239

ADVAXIS 239









AERAS GLOBAL 240

ALPHAVAX INC. 241

ASTELLAS PHARMA INC. 241

ASTRAZENECA PLC 242

BAXTER INTERNATIONAL INC. 243

BAYER HEALTHCARE ANIMAL HEALTH 244

BHARAT BIOTECH INTERNATIONAL LTD. 245

BIOLOGICAL E. LTD. 246

BIO-MANGUINHOS 246

BIOPROPERTIES 247

BOEHRINGER INGELHEIM GMBH 247

BUL BIO-NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES LTD.

(BB-NCIPD LTD.) 248

CADILA HEALTHCARE LTD. 249

CEVA SANTE ANIMALE 249

CHINA NATIONAL BIOTEC GROUP (CNBG) 251

COLORADO SERUM CO. 252

CRUCELL 252

CSL LTD. 254

ELANCO ANIMAL HEALTH 254

EMERGENT BIOSOLUTIONS INC. 255

FATRO SPA 256

GENVEC INC. 257

GEOVAX 258

GLAXOSMITHKLINE PLC 259

GREEN CROSS CORP. 260

HESKA CORP. 261

IMMUNE SOLUTIONS LTD. 261

INSTITUT PASTEUR DE DAKAR 262

INTERCELL AG 262

JAPAN BCG LABORATORY 264

LG LIFE SCIENCES 264

LOHMANN ANIMAL HEALTH INTERNATIONAL 265

MERCK & CO. INC. 266

MERIAL INC. 267

NIPPON BIOLOGICALS INC. 268

NOVARTIS AG 269

OKAIROS AG 270

PANACEA BIOTEC LTD. 271

PFENEX INC. 271

PFIZER 273

PROFECTUS BIOSCIENCES INC. 274

PT BIO FARMA 275

SANOFI PASTEUR 276

SERUM INSTITUTE OF INDIA LTD. 277

SHANTHA BIOTECHNICS LTD. 278

STATENS SERUM INSTITUT 279

VGX INTERNATIONAL INC. 279









VIRBAC 280

ZOETIS INC. 280

CHAPTER 13 APPENDIX I 284

ABBREVIATIONS 284

LIST OF TABLES

SUMMARY TABLE GLOBAL SALES OF HUMAN AND ANIMAL VACCINES, THROUGH

2017 ($ MILLIONS) 9

TABLE 1 HISTORY OF VACCINES 12

TABLE 2 TYPES OF ATTENUATED (LIVE) VACCINES 15

TABLE 3 ADVANTAGES AND DISADVANTAGES OF ATTENUATED (LIVE) VACCINES 16

TABLE 4 TYPES OF INACTIVATED (KILLED) VACCINES 17

TABLE 5 ADVANTAGES AND DISADVANTAGES OF INACTIVATED (KILLED) VACCINES 18

TABLE 6 TYPES OF TOXOID VACCINES 19

TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES 19

TABLE 8 TYPES OF SUBUNIT VACCINES 20

TABLE 9 ADVANTAGES AND DISADVANTAGES OF SUBUNIT VACCINES 21

TABLE 10 TYPES OF CONJUGATE VACCINES 22

TABLE 11 ADVANTAGES AND DISADVANTAGES OF CONJUGATE VACCINES 22

TABLE 12 TYPES OF RECOMBINANT VECTOR VACCINES 23

TABLE 13 ADVANTAGES AND DISADVANTAGES OF RECOMBINANT VECTOR

VACCINES 24

TABLE 14 TYPES OF DNA VACCINES 25

TABLE 15 ADVANTAGES AND DISADVANTAGES OF DNA VACCINES 25

TABLE 16 VACCINE-PREVENTABLE HUMAN VIRAL DISEASES 27

TABLE 17 VACCINE-PREVENTABLE HUMAN BACTERIAL DISEASES 29

TABLE 18 VACCINE-PREVENTABLE ANIMAL DISEASES FOUND IN FOOD PRODUCING

ANIMALS 32

TABLE 19 VACCINE-PREVENTABLE ANIMAL DISEASES FOUND IN COMPANION

ANIMALS 35

TABLE 20 VACCINE-PREVENTABLE ANIMAL DISEASES FOUND IN OTHER ANIMALS 36

TABLE 21 ANIMAL VACCINES FOR FOOD-PRODUCING, COMPANION AND OTHER

ANIMALS 37

TABLE 22 NATIONAL REGULATORY AUTHORITIES OF VACCINES ACROSS REGIONS 44

TABLE 23 REVISIONS TO EXISTING VACCINES, 2010 THROUGH 2012 46

TABLE 24 NEWLY APPROVED VACCINES, 2010 THROUGH 2012 51

TABLE 25 GLOBAL VACCINE RECALLS, 2010 THROUGH 2012 52

TABLE 26 REPORTED INCIDENCE DATA OF HUMAN DISEASES (NO.) 56

TABLE 27 IMMUNIZATION COVERAGE DATA OF HUMAN DISEASES (%) 57

TABLE 28 REPORTED CASES OF VACCINE-PREVENTABLE HUMAN DISEASES

WORLDWIDE, 2010 AND 2011 (NO.) 58

TABLE 29 IMMUNIZATION COVERAGE OF VACCINE-PREVENTABLE HUMAN DISEASES

WORLDWIDE, 2010 AND 2011 (%) 59

TABLE 30 UPTAKE OF NEW AND UNDERUSED VACCINES, 2011 (NO.) 59

TABLE 31 DEATHS OF CHILDREN GLOBALLY DUE TO DISEASES PREVENTABLE WITH

VACCINES, 2011 (NO.) 60

TABLE 32 ESTIMATED FUTURE DEATHS AVERTED WITH VACCINES, 2011-2020









(MILLIONS) 61

TABLE 33 HUMAN VACCINES IN THE RESEARCH PIPELINE AS OF 2012 64

TABLE 34 ALLIANCES, JOINT VENTURES AND AWARDS FOR THE DEVELOPMENT OF

HUMAN AND ANIMAL VACCINES, 2010-2012 71

TABLE 35 GLOBAL SALES OF VACCINES BY CATEGORY, THROUGH 2017 ($ MILLIONS) 78

TABLE 36 GLOBAL MARKET SHARES OF VACCINE SALES BY CATEGORY, 2011 (%) 79


MILLIONS) 82

TABLE 38 GLOBAL MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2011

(%) 83


MILLIONS) 86

TABLE 40 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2011

(%) 87

TABLE 41 GLOBAL SALES OF VACCINES BY REGION, THROUGH 2017 ($ MILLIONS) 90

TABLE 42 GLOBAL MARKET SHARES OF VACCINE SALES BY REGION, 2011 (%) 91

TABLE 43 GLOBAL SALES OF HUMAN VACCINES BY APPLICATION, THROUGH 2017 ($

MILLIONS) 94


2011 (%) 96

TABLE 45 MARKET SHARES OF TOP-SELLING VACCINES BY APPLICATION, 2011 (%) 97


MILLIONS) 101

TABLE 47 MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2011 (%) 102

TABLE 48 GLOBAL SALES OF HUMAN VACCINES BY REGION, THROUGH 2017 ($

MILLIONS) 105

TABLE 49 MARKET SHARES OF HUMAN VACCINE SALES BY REGION, 2011 (%) 106

TABLE 50 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINES BY REGION,


TABLE 51 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES BY REGION,


TABLE 52 GLOBAL MARKET FOR CONJUGATE VACCINES BY REGION, THROUGH 2017

($ MILLIONS) 113

TABLE 53 GLOBAL MARKET FOR RECOMBINANT/RDNA/DNA VACCINES BY REGION,


TABLE 54 GLOBAL MARKET FOR SUBUNIT VACCINES BY REGION, THROUGH 2017 ($

MILLIONS) 118

TABLE 55 GLOBAL MARKET FOR TOXOID VACCINES BY REGION, THROUGH 2017 ($

MILLIONS) 119

TABLE 56 GLOBAL MARKET FOR OTHER/COMBINATION VACCINES BY REGION,


TABLE 57 HUMAN VACCINES BASED ON MICROORGANISM 123

TABLE 58 GLOBAL SALES OF HUMAN VACCINES FOR

MENINGOCOCCAL/PNEUMOCOCCAL DISEASES, THROUGH 2017 ($ MILLIONS) 126

TABLE 59 MARKET SHARES OF TOP-SELLING MENINGOCOCCAL/PNEUMOCOCCAL

VACCINES, 2011 (%) 127

TABLE 60 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET,










TABLE 61 MARKET SHARES OF TOP-SELLING INFLUENZA VACCINES, 2011 (%) 131

TABLE 62 GLOBAL SALES OF HUMAN VACCINES PEDIATRIC POLIO/PERTUSSIS/HIB

DISEASES MARKET, THROUGH 2017 ($ MILLIONS) 133TABLE 63 MARKET SHARES OF TOP-SELLING PEDIATRIC

POLIO/PERTUSSIS/HIB

VACCINES, 2011 (%) 134

TABLE 64 GLOBAL SALES OF HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER


TABLE 65 MARKET SHARES OF TOP-SELLING ADULT/ADOLESCENT BOOSTER

VACCINES, 2011 (%) 137

TABLE 66 GLOBAL SALES OF HUMAN VACCINES FOR TRAVEL-RELATED AND OTHER

ENDEMIC DISEASES, THROUGH 2017 ($ MILLIONS) 139

TABLE 67 MARKET SHARES OF TOP-SELLING VACCINES FOR TRAVEL-RELATED AND

OTHER ENDEMIC DISEASES, 2011 (%) 141

TABLE 68 GLOBAL SALES OF HUMAN VACCINES IN HPV, THROUGH 2017 ($ MILLIONS) 142

TABLE 69 MARKET SHARES OF TOP-SELLING HPV VACCINES, 2011 (%) 143

TABLE 70 GLOBAL SALES OF HUMAN VACCINES IN ROTAVIRUS MARKET, THROUGH

2017 ($ MILLIONS) 144

TABLE 71 MARKET SHARES OF TOP-SELLING ROTAVIRUS VACCINES, 2011 (%) 145

TABLE 72 GLOBAL SALES OF HUMAN VACCINES IN THE OTHER DISEASES SEGMENT,


TABLE 73 MARKET SHARES OF TOP-SELLING VACCINES IN THE OTHER DISEASES

SEGMENT, 2011 (%) 149


2011 (%) 150

TABLE 75 LEADING MANUFACTURERS/SUPPLIERS OF HUMAN VACCINES 151

TABLE 76 MANUFACTURER/PROCESSORS' MARKET SHARES OF HUMAN VACCINE

SALES, 2011 (%) 157

TABLE 77 GLOBAL SALES OF ANIMAL HEALTH PRODUCTS BY MARKET LEADER,

2010'2012 ($ MILLIONS) 162


MILLIONS) 165

TABLE 79 GLOBAL MARKET FOR VACCINES FOR FOOD-PRODUCING ANIMALS BY

REGION, THROUGH 2017 ($ MILLIONS) 167

TABLE 80 GLOBAL MARKET FOR VACCINES FOR COMPANION ANIMALS BY REGION,


TABLE 81 GLOBAL MARKET FOR OTHER ANIMAL VACCINES BY REGION, THROUGH

2017 ($ MILLIONS) 171

TABLE 82 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2011

(%) 172

TABLE 83 GLOBAL SALES OF ANIMAL VACCINES BY REGION, THROUGH 2017 ($

MILLIONS) 175

TABLE 84 MARKET SHARES OF ANIMAL VACCINE SALES BY REGION, 2011 (%) 176

TABLE 85 LEADING MANUFACTURERS/SUPPLIERS OF ANIMAL VACCINES 176

TABLE 86 MANUFACTURER/PROCESSORS' MARKET SHARES OF ANIMAL VACCINE

SALES, 2011 (%) 179

TABLE 87 U.S. PATENTS GRANTED FOR HUMAN AND ANIMAL VACCINES BY YEAR,

2010'2012 (NO.) 183

TABLE 88 U.S. PATENTS GRANTED FOR HUMAN AND ANIMAL VACCINES BY TYPE,









2010'2012 (NO.) 184



TABLE 90 SHARES OF U.S. PATENTS ON ATTENUATED (LIVE) VACCINES BY

ASSIGNEE'S COUNTRY, 2010-2012 (NUMBER/%) 186



TABLE 92 SHARES OF U.S. PATENTS ON INACTIVATED (KILLED) VACCINES BY

ASSIGNEE'S COUNTRY, 2010'2012 (NUMBER/%) 189

TABLE 93 U.S. PATENTS GRANTED FOR TOXOID VACCINES BY ASSIGNEE'S COUNTRY,

2010'2012 (NO.) 190

TABLE 94 SHARES OF U.S. PATENTS ON TOXOID VACCINES BY ASSIGNEE'S

COUNTRY, 2010'2012 (%) 191

TABLE 95 U.S. PATENTS GRANTED FOR SUBUNIT VACCINES BY ASSIGNEE'S

COUNTRY, 2010'2012 (NO.) 192

TABLE 96 SHARES OF U.S. PATENTS ON SUBUNIT VACCINES BY ASSIGNEE'S

COUNTRY, 2010'2012 (%) 193

TABLE 97 U.S. PATENTS GRANTED FOR CONJUGATE VACCINES BY ASSIGNEE'S

COUNTRY, 2010'2012 (NO.) 194

TABLE 98 SHARES OF U.S. PATENTS ON CONJUGATE VACCINES BY ASSIGNEE'S

COUNTRY, 2010'2012 (%) 195



TABLE 100 SHARES OF U.S. PATENTS ON RECOMBINANT/RDNA/DNA VACCINES BY




TABLE 102 SHARES OF U.S. PATENTS ON OTHER/COMBINATION VACCINES BY



COMPANY, 2010'2012 (NO.) 202

TABLE 104 U.S. PATENTS GRANTED ON INACTIVATED (KILLED) VACCINES BY

COMPANY, 2010'2012 (NO.) 204

TABLE 105 U.S. PATENTS GRANTED ON SUBUNIT VACCINES BY COMPANY,

2010'2012 (NO.) 205

TABLE 106 U.S. PATENTS GRANTED ON CONJUGATE VACCINES








>> Get this Report Now by email!Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93

If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require.

Product Formats Please select the product formats and the quantity you require.

Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________

Global Markets for Vaccine Technologies

1 User License--USD 5 450.00 Quantity: _____

Department License--USD 6 650.00 Quantity: _____

Corporate License--USD 9 350.00 Quantity: _____








>> Get this Report Now by email!Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card

Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer

Crédit Mutuel

RIB : 10278 07314 00020257701 89

BIC : CMCIFR2A

IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check

UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at

http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93

Customer signature:







global markets for vaccine technologies

Documents

vaccine market trends

market shares of vaccine

present market

market leaders

market forecasts

vaccine typescategories

animal vaccine technologies

vaccine technologiespublished